The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Abstract
OBJECTIVE: To determine if lowering elevated low-density lipoprotein cholesterol (LDL-C) levels offsets the adverse effect of raised lipoprotein(a) (Lp[a]) levels on coronary artery disease (CAC) in men. DESIGN: Randomized, double-blind, placebo-controlled trial of lipid lowering for CAD. SETTING: Post hoc analysis of the Familial Atherosclerosis Treatment Study. PARTICIPANTS: A total of 146 men aged 62 years or younger with CAD and apolipoprotein B levels of at least 125 mg/dL. INTERVENTION: Patients received a Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily), niacin (4 g daily) plus colestipol, or placebo (plus colestipol if LDL-C > 90th percentile) for 2.5 years. They were grouped by their LDL-C responses: "minimal" if LDL-C decreased by 10% or less from baseline (mean [SD] change, +6% [13%]) and "substantial" if LDL-C decreased more than 10% (mean [SD] change, -40% [16%]). MAIN OUTCOME MEASURE: Impact of lowering elevated LDL-C on the cardiac event rate (death, myocardial infarction, and revascularization for refractory ischemia) and CAD change associated with elevated Lp(a). RESULTS: In multivariate analyses, the best correlate of baseline CAD severity was Lp(a) (r = 0.30; P < .001). For 36 patients with minimal LDL-C reduction, CAD progression correlated only with in-treatment Lp(a) levels (r = 0.45; P < .01), but for 84 patients with substantial LDL-C reduction, disease regressed and its change correlated with in-treatment LDL-C (r = 0.24; P < .05) but not with Lp(a) (r = -0.05). Lipoprotein(a) levels were not significantly altered in either group. For 40 patients with Lp(a) at the 90th percentile or higher, events were frequent (39%) if reduction of LDL-C was minimal, but were few (9%) if reduction was substantial (relative risk, 0.23; 95% confidence interval, 0.06 to 0.99). CONCLUSIONS: In men with CAD and elevated LDL-C, Lp(a) levels were dominant correlates of baseline disease severity, its progression, and event rate over 2.5 years. However, with substantial LDL-C reductions, persistent elevations of Lp(a) were no longer atherogenic or clinically threatening. This provides a possible direction for treatment in such patients with elevated Lp(a) and LDL-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lp(a) Lipoprotein as a Risk Factor for Myocardial Infarction
Rhoads, G. G. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380180102027 · Cited by 783
Armstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H., & Seidel, D. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90099-7 · Cited by 626
Seed, M., Hoppichler, F., Reaveley, D., McCarthy, S., Thompson, G. R., Boerwinkle, E., & Utermann, G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005243222104 · Cited by 585
Rosengren, A., Wilhelmsen, L., Eriksson, E., Risberg, B., & Wedel, H. (1990) · BMJ · doi:10.1136/bmj.301.6763.1248 · Cited by 539
A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
Ridker, P. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180065035 · Cited by 512
Schaefer, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510370051031 · Cited by 487
Lipoprotein(a), fibrin binding, and plasminogen activation.
Loscalzo, J., Weinfeld, M., Fless, G. M., & Scanu, A. M. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.2.240 · Cited by 461
Human plasma lipoprotein [a]. Structural properties.
Gaubatz, J. W., Heideman, C., Gotto, A. M., Morrisett, J. D., & Dahlen, G. H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32663-2 · Cited by 453
Cited by
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 605
Metadata
- Authors
- Maher, V. M. G.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1995-12-13
- Volume
- 274
- Issue
- 22
- Pages
- 1771
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2085713634
- Cited by
- 298
- References
- 27
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a). https://app.cochat.ai/papers/10.1001/jama.1995.03530220037029
- The paper
- Maher, V. M. G. (1995). Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a). JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1995.03530220037029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.